We are thrilled to announce @GenEndeavor’s participation in the upcoming BIO CEO & Investor Conference, in New York City, NY, on February 26-27, 2024.
At the event, GenEndeavor will showcase our Non-Enzymatic Amplification Technologies (NEAT) platform to usher in a new generation of technologies for molecular diagnostics.
At GenEndeavor, we’re toolmakers with a mission to translate our new platform into early-detection tests to enable ovarian cancer screening, one-hour sepsis pathogen identification directly in uncultured blood, point-of-care TB testing in non-sputum samples, and rapid detection of airborne pathogens at the point of presentation.
As toolmakers, we’re looking for partnerships to deliver the final NEAT tools. If you're attending the conference, we would like to connect with you and have discussions on how we can partner in developing breakthrough technology for the early detection of infectious and genetic diseases using a non-enzymatic isothermal paradigm. #LifeSciences #InnovationInHealthcare